isradipine? why? elite had nothing to do with the study. They used generic isradipine and IF a label issues it will be class labeling for all. Elite has a minute fraction of the market share now and there is no evidence to support that argument they will grow market share. Elite has gross margins about half of generic manufactures thus they cannot win in a price war. Finally there are others approved who voluntarily discontinued that could reenter the market in a few short months. as always, I try to be open minded but I havent heard a compelling argument to the contrary